Gerresheimer's Turnaround Strategy Emerges Amid Accounting Crisis and Rejected Bid

Gerresheimer secures debt extension to 2026, rejects Silgan's €41/share offer, and plans asset sale after €240M impairments from accounting breaches.

A rejected takeover offer worth more than double its share price and a critical debt extension are defining the path forward for Gerresheimer. The Düsseldorf-based pharmaceutical packaging specialist is navigating a severe accounting scandal, choosing to pursue an independent restructuring over a lucrative exit. This decision comes as the company grapples with expected non-cash impairments of up to €240 million stemming from internal financial misstatements.

The company recently secured vital breathing room from its creditors. Holders of 96% of its €870 million in Schuldschein loans agreed to extend a key deadline until the end of September 2026. They also temporarily suspended major covenants related to leverage ratios, providing management with crucial operational flexibility. This lifeline has been a key driver behind a recent 26% surge in the share price over seven days, though the stock remains down 57% over the past twelve months, trading at €22.24.

At the heart of the crisis are systematic breaches of accounting rules. An independent law firm confirmed violations involving so-called "bill-and-hold" agreements, where revenue was booked for goods invoiced but not yet delivered. These errors amounted to €35 million in revenue and €24 million in adjusted EBITDA. The German financial regulator, BaFin, is investigating indications of incorrect financial statements.

The fallout is spreading. The audit oversight body APAS has initiated professional misconduct proceedings against auditor KPMG, which issued an unqualified audit opinion for the previous year despite these issues. KPMG had only just replaced the previous auditor, Deloitte, in 2024. Shareholder association DSW is examining damage claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner, with questions also surrounding business valuations totaling approximately €676 million.

To strengthen its capital structure, Gerresheimer is pushing ahead with the sale of its US subsidiary, Centor. The unit, which manufactures packaging systems for prescription drugs in the US, was carried on the books at €292 million at the end of 2024. Investment bank Morgan Stanley is running the process, with a double-digit number of interested parties already involved. Management aims to complete the transaction this year.

This strategic move follows the company's rejection of an unsolicited approach. According to sources cited by Reuters, US rival Silgan made a non-binding offer of €41 per share in March, talks for which are no longer active. Instead of pursuing a sale, Gerresheimer is focusing on resolving its balance sheet issues internally. The news initially pushed the share price down 5%, but it quickly recovered, with institutional investors like the CastleKnight Master Fund and Deka Investment reporting new stakes.

Operationally, the company maintains its targets. It aims for revenue of up to €2.4 billion and an adjusted EBITDA margin of around 18% by 2026, asserting that day-to-day business is performing within expectations. The financial calendar, however, remains disrupted. The audited annual and group financial statements for 2025 are now scheduled for release in June 2026, with the half-year report due on July 14, 2026. No date has been set for an annual general meeting.

The coming months present a clear test. Successfully publishing the audited financials by mid-2026 would remove a major overhang, while a timely sale of Centor is crucial for debt reduction. Until then, every new development from the regulatory front remains a potential catalyst for the volatile stock.